{"id":154,"date":"2011-04-12T15:41:48","date_gmt":"2011-04-12T20:41:48","guid":{"rendered":"http:\/\/www.wilsonpr.com\/?p=154"},"modified":"2011-04-12T15:41:48","modified_gmt":"2011-04-12T20:41:48","slug":"p2d-bioscience-lead-adhd-drug-demonstrates-efficacy-in-preclinical-testing","status":"publish","type":"post","link":"https:\/\/www.wilsonpr.com\/?p=154","title":{"rendered":"P2D Bioscience Lead ADHD Drug Demonstrates Efficacy in Preclinical Testing"},"content":{"rendered":"<p><a href=\"http:\/\/www.p2dinc.com\"><img decoding=\"async\" loading=\"lazy\" class=\"alignleft size-medium wp-image-155\" title=\"P2D logonoline-2\" src=\"http:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2-300x83.jpg\" alt=\"\" width=\"240\" height=\"66\" srcset=\"https:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2-300x83.jpg 300w, https:\/\/www.wilsonpr.com\/wp-content\/uploads\/2011\/04\/P2D-logonoline-2.jpg 404w\" sizes=\"(max-width: 240px) 100vw, 240px\" \/><\/a>P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit\/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of <a href=\"http:\/\/www.p2dinc.com\/products.html\">ADHD<\/a> in preclinical ADHD models.\u00a0 The independently conducted studies were funded by a grant from the National Institutes of Health (NIH).<\/p>\n<p><a href=\"http:\/\/www2.marketwire.com\/mw\/release_html_b1?release_id=743285\" target=\"_blank\">Click here<\/a> to read the entire release.<\/p>\n<p><a href=\"http:\/\/www2.marketwire.com\/mw\/release_html_b1?release_id=743285\"><br \/>\n<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit\/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models.\u00a0 The independently conducted studies were funded by a grant from the National Institutes of Health (NIH). Click here to read the entire [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[56,55],"_links":{"self":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/154"}],"collection":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=154"}],"version-history":[{"count":1,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/154\/revisions"}],"predecessor-version":[{"id":156,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=\/wp\/v2\/posts\/154\/revisions\/156"}],"wp:attachment":[{"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wilsonpr.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}